Differences Between Patients' And General Population's Measures Of Quality Of Life Vary Dependent Upon Health Problems

Published May 15, 2014
Munich, Germany - The valuation of health states is a critical part of economic evaluation studies. Health states can be valued by those who currently experience a health state or by the general public, who try to imagine what it is like to be in a health state. Differences between these methods have sparked debate over which is more appropriate when making resource allocation decisions within a health care system. Patient values better reflect the actual experience of a state, while the general population values reflect aspects of a societal perspective of how resources should be allocated. When deciding which of these perspectives is more relevant, it is useful to consider the impact of the choice. A research team from the Helmholtz Centre in Munich assessed how the differences in health state valuations impact quality of life assessments in disease groups such as those who suffered strokes, heart attacks, diabetes and cancer. The results of their study showed that differences between the methods were dependent on the health problems faced by the disease groups. Research assistant and first author of the study, Matthew Little, MSc, says, “The results were surprising because although the experience values tended to be higher than the population values for the majority of health states, its use gave relatively lower level of quality of life for the majority of the disease groups. As a result, health care decision makers should consider these findings when deciding whose values should count.” The full study, “The Impact of Differences between Patient and General Population EQ-5D-3L Values on the Mean Tariff Scores of Different Patient Groups,” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×